MedTrace Logo

A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease

NCT00675623 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 598

Last updated 2016-09-27

No results posted yet for this study

Summary

The Connection Study is a six-month confirmatory Phase 3 study to determine the safety and efficacy of Dimebon in the treatment of mild-to-moderate Alzheimer's disease (AD).

Conditions

Interventions

DRUG

Dimebon

Dimebon, 5 mg orally three times daily for six months

DRUG

Dimebon

Dimebon 20 mg orally three times daily for six months

DRUG

Placebo

Placebo three times daily for six months

Sponsors & Collaborators

  • Medivation, Inc.

    lead INDUSTRY

Principal Investigators

  • Lynn Seely, MD · Medivation, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00675623 on ClinicalTrials.gov